Marrone Bio Innovations (NasdaqCM:MBII) - Share price, News & Analysis

MBII fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

MBII Stock Overview

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition.

Rewards

Revenue is forecast to grow 24.75% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Marrone Bio Innovations Competitors

Kenongwo Group US

OTCPK:KNGW

US$255.7m

Bioceres Crop Solutions

NasdaqGS:BIOX

US$545.9m

AgroFresh Solutions

NasdaqGS:AGFS

US$91.1m

Intrepid Potash

NYSE:IPI

US$616.3m

Price History & Performance

Summary of all time highs, changes and price drops for Marrone Bio Innovations
Historical stock prices
Current Share Price	US$1.09
52 Week High	US$1.70
52 Week Low	US$0.55
Beta	0.36
1 Month Change	-3.54%
3 Month Change	0.93%
1 Year Change	-34.34%
3 Year Change	-23.24%
5 Year Change	-12.10%
Change since IPO	-92.07%

Shareholder Returns

	MBII	US Chemicals	US Market
7D	12.7%	-0.09%	1.6%
1Y	-34.3%	-11.1%	-20.8%

Return vs Industry: MBII underperformed the US Chemicals industry which returned -10% over the past year.

Return vs Market: MBII underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is MBII's price volatile compared to industry and market?
MBII volatility
MBII Average Weekly Movement	11.9%
Chemicals Industry Average Movement	6.8%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.2%

Stable Share Price: MBII is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MBII's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2006	153	Kevin Helash	https://www.marronebio.com

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health.

Marrone Bio Innovations Fundamentals Summary

How do Marrone Bio Innovations's earnings and revenue compare to its market cap?
MBII fundamental statistics
Market Cap	US$198.79m
Earnings (TTM)	-US$20.89m
Revenue (TTM)	US$44.37m

4.5x

P/S Ratio

-9.5x

P/E Ratio

Is MBII overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MBII income statement (TTM)
Revenue	US$44.37m
Cost of Revenue	US$17.89m
Gross Profit	US$26.48m
Other Expenses	US$47.37m
Earnings	-US$20.89m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.11
Gross Margin	59.69%
Net Profit Margin	-47.08%
Debt/Equity Ratio	139.3%

How did MBII perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is MBII undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MBII?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MBII. This is calculated by dividing MBII's market cap by their current preferred multiple.
What is MBII's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$198.79m

MBII key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.1x
Enterprise Value/EBITDA	-14.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MBII's PS Ratio compare to its peers?

MBII PS Ratio vs Peers

The above table shows the PS ratio for MBII vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	28.2x
KNGW Kenongwo Group US	108.1x	n/a	US$255.7m
BIOX Bioceres Crop Solutions	1.8x	18.6%	US$545.9m
AGFS AgroFresh Solutions	0.5x	9.3%	US$91.1m
IPI Intrepid Potash	2.4x	-9.9%	US$616.3m
MBII Marrone Bio Innovations	4.5x	24.7%	US$198.8m

Forward PS

Price-To-Sales vs Peers: MBII is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (28.2x).

Price to Earnings Ratio vs Industry

How does MBII's PE Ratio compare vs other companies in the US Chemicals Industry?

Price-To-Sales vs Industry: MBII is expensive based on its Price-To-Sales Ratio (4.5x) compared to the US Chemicals industry average (1.3x)

Price to Sales Ratio vs Fair Ratio

What is MBII's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MBII PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.5x
Fair PS Ratio	5.6x

Price-To-Sales vs Fair Ratio: MBII is good value based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (5.6x).

Share Price vs Fair Value

What is the Fair Price of MBII when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MBII's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MBII's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MBII's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Marrone Bio Innovations forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

70.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBII is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBII is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBII is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MBII's revenue (24.7% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: MBII's revenue (24.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MBII's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Marrone Bio Innovations performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

8.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MBII is currently unprofitable.

Growing Profit Margin: MBII is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MBII is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare MBII's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MBII is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (30.2%).

Return on Equity

High ROE: MBII has a negative Return on Equity (-91.33%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Marrone Bio Innovations's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MBII's short term assets ($33.0M) do not cover its short term liabilities ($41.7M).

Long Term Liabilities: MBII's short term assets ($33.0M) exceed its long term liabilities ($11.6M).

Debt to Equity History and Analysis

Debt Level: MBII's net debt to equity ratio (98.4%) is considered high.

Reducing Debt: MBII had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MBII has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MBII has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.3% each year.

Discover healthy companies

Dividend

What is Marrone Bio Innovations's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MBII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MBII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MBII's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MBII's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MBII has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure

CEO

Kevin Helash (56 yo)

1.83yrs

Tenure

US$416,642

Compensation

Mr. Kevin R. Helash serves as Chief Executive Officer and Director at Marrone Bio Innovations, Inc. since August 03, 2020. He had been the Chief Executive Officer of Agrinos AS since November 20, 2017 unti...

CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD416.64K) is below average for companies of similar size in the US market ($USD1.76M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: MBII's management team is considered experienced (4.5 years average tenure).

Board Members

Experienced Board: MBII's board of directors are considered experienced (4 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.

Data	Last Updated (UTC time)
Company Analysis	2022/06/29 00:00
End of Day Share Price	2022/06/29 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31